Ignite Creation Date:
2025-12-24 @ 4:09 PM
Ignite Modification Date:
2025-12-27 @ 3:08 AM
Study NCT ID:
NCT04079166
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-19
First Post:
2019-08-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Sponsor:
Scancell Ltd
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-08-19
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-01-31
Completion Date Type:
ESTIMATED
First Submit Date:
2019-08-16
First Submit QC Date:
None
Study First Post Date:
2019-09-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-12
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED